Trial Profile

A phase I clinical trial Fibroblast growth factor 1 in subjects with lung damage from COVID-19

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fibroblast growth factor 1 (Primary)
Indications COVID 2019 infections; Lung disorders
Focus Adverse reactions

Most Recent Events

23 Jun 2020 New trial record
17 Jun 2020 According to a Zhittya Genesis Medicine media release, company plans to file an Investigational New Drug (IND) application with the US FDA to initiate this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com